MAGI2 is an independent predictor of biochemical recurrence in prostate cancer.
Stephanie N DavidShanna A Arnold EgloffRajen GoyalPeter E ClarkSharon PhillipsLan L GellertOmar HameedGiovanna A GiannicoPublished in: The Prostate (2018)
These results reveal that MAGI2 expression is reduced during prostate cancer progression and that retention of MAGI2 signal reduces odds of BCR. The study results further suggest a possible role of MAGI2 in prostate neoplasia. Decreased MAGI2 expression may help predict prostate cancer aggressiveness and provide new insight for treatment decisions and post-operative surveillance intervals.